ABX 464

Drug Profile

ABX 464

Alternative Names: ABX-464

Latest Information Update: 05 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Splicos
  • Developer Abivax
  • Class Anti-inflammatories; Antivirals; Small molecules
  • Mechanism of Action Immunostimulants; Viral RNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II HIV infections; Ulcerative colitis

Most Recent Events

  • 01 Jan 2018 Abivax initiates enrolment in a follow up phase IIa trial for Ulcerative collitis in Belgium (NCT03368118)
  • 15 Dec 2017 Efficacy data from a phase IIa trial in HIV infections released by Abivax
  • 11 Dec 2017 Abivax S.A. plans a phase II trial for Ulcerative Colitis in January 2018 (NCT03368118),
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top